Cite
L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia.
MLA
Ponomareva, Olga Y., et al. “L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia.” Schizophrenia Bulletin Open, vol. 2, no. 1, Jan. 2020, pp. 1–9. EBSCOhost, https://doi.org/10.1093/schizbullopen/sgaa026.
APA
Ponomareva, O. Y., Redman, B., Sayer, M. A., Wehring, H. J., Vyas, G., Richardson, C. M., Gold, J. M., Gorelick, D. A., Cihakova, D., Talor, M. V., Hoag, S. W., Buchanan, R. W., Jingtao Wang, Shuo Chen, Fang Liu, Jia Bei Wang, & Kelly, D. L. (2020). L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia. Schizophrenia Bulletin Open, 2(1), 1–9. https://doi.org/10.1093/schizbullopen/sgaa026
Chicago
Ponomareva, Olga Y., Brianne Redman, MacKenzie A. Sayer, Heidi J. Wehring, Gopal Vyas, Charles M. Richardson, James M. Gold, et al. 2020. “L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia.” Schizophrenia Bulletin Open 2 (1): 1–9. doi:10.1093/schizbullopen/sgaa026.